Nov. 10 at 9:08 PM
$SNES Q3 2025 Financial Highlights
Revenues increased by 43% to
$690,000, a record for the Company, from
$482,000 in Q3 2024.
Evolve® Rodent Birth Control product sales grew 77% year-over-year, now representing 85% of total revenue.
Gross profit margin was 62.8%, in line with expectations.
Net loss for Q3 2025 was
$1.3 million, compared to
$1.5 million in Q3 2024. Q3 2025 included
$111,000 in one-time legal expenses and
$49,000 in non-cash operating lease expense. Excluding these non-operational costs, the Company's net loss would have been
$1.1 million for Q3 2025.
Adjusted EBITDA loss improved to
$1.2 million in Q3 2025, a record for the Company, compared to
$1.4 million in the same quarter of the prior year.
Cash and short-term investments of
$10.2 million provide the Company with a solid operating runway for the foreseeable future.
